These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17942884)

  • 1. Trastuzumab--mechanism of action and use.
    Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
    N Engl J Med; 2007 Oct; 357(16):1664; author reply 1665-6. PubMed ID: 17942884
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in HER2-positive breast cancer.
    Sledge GW
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):98-100. PubMed ID: 18347559
    [No Abstract]   [Full Text] [Related]  

  • 3. Trastuzumab--mechanism of action and use in clinical practice.
    Hudis CA
    N Engl J Med; 2007 Jul; 357(1):39-51. PubMed ID: 17611206
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3.
    Menendez JA; Lupu R
    J Clin Oncol; 2007 Jun; 25(17):2496-8; author reply 2499. PubMed ID: 17557968
    [No Abstract]   [Full Text] [Related]  

  • 5. Managing trastuzumab-resistant breast cancer.
    Krop I
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
    [No Abstract]   [Full Text] [Related]  

  • 6. [Breast Cancer Conference. Trastuzumab and capecitabine in the treatment of advanced breast cancer. Milano, 6-7 June 2002].
    Longo F; Mansueto G
    Tumori; 2002; 88(5):A1-10. PubMed ID: 12489530
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
    Poncet B; Bachelot T; Colin C; Orfeuvre H; Ganne C; Péaud PY; Jacquin JP; Salles B; Tigaud JD; Méchin-Crétinon I; Maréchal F; Trillet-Lenoir V
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):162-3. PubMed ID: 17357239
    [No Abstract]   [Full Text] [Related]  

  • 8. Gastric cancer: trastuzumab trial results spur search for other targets.
    Hede K
    J Natl Cancer Inst; 2009 Oct; 101(19):1306-7. PubMed ID: 19755679
    [No Abstract]   [Full Text] [Related]  

  • 9. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions.
    Bernard-Marty C; Lebrun F; Awada A; Piccart MJ
    Drugs; 2006; 66(12):1577-91. PubMed ID: 16956305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
    Reed SD; Schulman KA
    Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
    [No Abstract]   [Full Text] [Related]  

  • 11. [Anti-HER2 therapy for breast cancer--an added increasing therapeutic option].
    Ito Y
    Gan To Kagaku Ryoho; 2010 Dec; 37(13):2845-9. PubMed ID: 21235090
    [No Abstract]   [Full Text] [Related]  

  • 12. Trastuzumab: is the new evidence revolutionary?
    Munshi A; Singh P; Jalali R
    J Cancer Res Ther; 2006; 2(3):144-6. PubMed ID: 17998695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 14. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
    Garnock-Jones KP; Keating GM; Scott LJ
    BioDrugs; 2010 Jun; 24(3):207-9. PubMed ID: 20462285
    [No Abstract]   [Full Text] [Related]  

  • 15. [The requirements to clinicopathology about targeted therapy for breast cancer].
    Jiang ZF; Shen G
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):435-7. PubMed ID: 17845752
    [No Abstract]   [Full Text] [Related]  

  • 16. [Isolated effect of the monoclonal antibody trastuzumab (Herceptin) in a patient with local recurrence of breast carcinoma with HER-2 hyperexpression. ].
    Del Giglio A
    Rev Assoc Med Bras (1992); 2006; 52(4):202. PubMed ID: 16967134
    [No Abstract]   [Full Text] [Related]  

  • 17. [Her2 a paradigm for targeted therapy].
    Marijon H; André F
    Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab in the treatment of breast cancer.
    Hortobagyi GN
    N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
    [No Abstract]   [Full Text] [Related]  

  • 19. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 20. Continuing trastuzumab beyond progression.
    Jahanzeb M
    J Clin Oncol; 2009 Apr; 27(12):1935-7. PubMed ID: 19289613
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.